This page provides a comprehensive comparison of three major neurodegenerative dementias: Dementia with Lewy Bodies (DLB), Parkinson's Disease (PD), and Alzheimer's Disease (AD). While these disorders share some pathological features, they have distinct clinical presentations, biomarker profiles, and treatment approaches.
This page provides a comprehensive comparison of three major neurodegenerative dementias: Dementia with Lewy Bodies (DLB), Parkinson's Disease (PD), and Alzheimer's Disease (AD). While these disorders share some pathological features, they have distinct clinical presentations, biomarker profiles, and treatment approaches.
| Feature | Dementia with Lewy Bodies | Parkinson's Disease | Alzheimer's Disease |
|---------|---------------------------|---------------------|---------------------|
| Primary Protein Pathology | [Alpha-synuclein](/proteins/alpha-synuclein) | [Alpha-synuclein](/proteins/alpha-synuclein) | [Amyloid-beta](/proteins/amyloid-beta), [Tau](/proteins/tau) |
| Key Inclusion Bodies | Lewy bodies, Lewy neurites | Lewy bodies, Lewy neurites | Amyloid plaques, neurofibrillary tangles |
| Onset Age | 50-80 years (mean ~75) | 50-80 years (mean ~65) | Typically >65 years |
| Prevalence | ~5% of dementia cases | ~1 million (USA) | ~6 million (USA) |
| Core Clinical Features | Visual hallucinations, fluctuating cognition, parkinsonism, RBD | Resting tremor, bradykinesia, rigidity, postural instability | Memory loss, cognitive decline |
| Cognitive Profile | Executive dysfunction, visuospatial deficits, fluctuating cognition | Executive dysfunction, later dementia | Memory encoding loss, progressive cognitive decline |
| Motor Symptoms | Present (50-70%), moderate | Core feature (100%), progressive | Late stage only |
| Disease Duration | 5-7 years average | 10-15 years average | 8-12 years average |
Both DLB and PD are classified as synucleinopathies characterized by abnormal accumulation of misfolded [alpha-synuclein](/proteins/alpha-synuclein) protein. The formation of Lewy bodies represents a common pathological endpoint:
Tau pathology is a feature of all three diseases, though with different patterns:
| Feature | DLB | PD | AD |
|---------|-----|-----|-----|
| Cognitive Fluctuation | Core (70-90%) | Variable | Rare |
| Visual Hallucinations | Core (60-80%) | Late (30-50%) | Late (10-20%) |
| Parkinsonism | Core (50-70%) | Core (100%) | Late (rare) |
| REM Sleep Behavior Disorder | Very common (60-80%) | Very common (50-70%) | Uncommon |
| Memory Loss | Early (retrieval) | Variable | Early (encoding) |
Dementia with Lewy Bodies:
| Feature | DLB | PD | AD |
|---------|-----|-----|-----|
| Bradykinesia | Common (50-70%) | Core (100%) | Rare, late |
| Resting Tremor | Less prominent | Core (70-90%) | Rare |
| Rigidity | Common | Core (80-90%) | Rare |
| Postural Instability | Common (late) | Common (50-70%) | Rare, late |
| Onset Pattern | Variable | Typically asymmetric | Symmetric |
| Symptom | DLB | PD | AD |
|---------|-----|-----|-----|
| Olfactory Dysfunction | Common | Core feature (>90%) | Common |
| Autonomic Dysfunction | Common (50-60%) | Common (30-50%) | Variable |
| Depression | Common (30-50%) | Common (30-50%) | Common (20-40%) |
| Psychosis | Core feature | Late feature | Late feature |
| REM Sleep Behavior Disorder | Very common | Very common | Uncommon |
| Modality | DLB | PD | AD |
|----------|-----|-----|-----|
| DaT-SPECT | Reduced striatal uptake | Reduced striatal uptake | Usually normal |
| FDG-PET | Occipital hypometabolism | Variable | Posterior cingulate, temporoparietal hypometabolism |
| MRI | Relative hippocampal preservation | Usually normal | Hippocampal atrophy |
| Amyloid PET | Variable (50% positive) | Usually negative | Positive |
| Biomarker | DLB | PD | AD |
|-----------|-----|-----|-----|
| Alpha-synuclein (seed amplification) | Positive | Positive | Negative |
| Total Tau | Elevated | Normal | Elevated |
| Phosphorylated Tau | Normal | Normal | Elevated |
| Amyloid-beta 1-42 | Normal or reduced | Normal | Reduced |
| Neurofilament Light Chain (NfL) | Elevated | Elevated | Elevated |
| Feature | DLB | PD | AD |
|---------|-----|-----|-----|
| Primary Inclusions | Lewy bodies (cortical) | Lewy bodies (brainstem > cortical) | amyloid plaques, NFT |
| Staging System | Braak α-syn (I-VI) | Braak α-syn (I-VI) | Braak NFT (I-VI), Thal amyloid |
| Neuronal Loss | Substantia nigra, locus coeruleus | Substantia nigra (prominent) | Hippocampus, cortex |
| Comorbid Pathology | Common (30-50% AD) | Common (up to 50% AD in PDD) | Primary |
| Treatment | DLB | PD | AD |
|-----------|-----|-----|-----|
| Cholinesterase Inhibitors | First-line (cognitive) | Limited | First-line |
| Memantine | May be used | Not used | First-line |
| Levodopa/Carbidopa | May help parkinsonism | First-line | Not indicated |
| Dopamine Agonists | Use with caution | First-line | Not indicated |
| Antipsychotics | Severe sensitivity | Use with caution | Use with caution |
DLB:
| Gene | DLB Risk | PD Risk | AD Risk |
|------|----------|---------|---------|
| [SNCA](/genes/snca) | Increased | Increased (causative) | No |
| [GBA](/genes/gba) | Increased | Increased | No |
| [LRRK2](/genes/lrrk2) | Increased | Increased (causative) | No |
| [APOE](/genes/apoe) ε4 | Increased | No | Strongly increased |
| [MAPT](/genes/mapt) | Increased | Increased | No effect |
| [C9orf72](/genes/c9orf72) | Rare | Rare | Rare |
| Phase | DLB | PD | AD |
|-------|-----|-----|-----|
| Prodromal | RBD, hyposmia, depression | RBD, hyposmia, depression | Subjective cognitive decline |
| Early | Cognitive + motor symptoms | Motor symptoms | MCI |
| Middle | Progressive cognitive decline | Motor complications | Progressive memory loss |
| Late | Severe disability | Severe motor/cognitive | Severe cognitive/functional decline |
While DLB, PD, and AD all represent neurodegenerative diseases with significant clinical impact, they differ in fundamental ways:
Understanding these distinctions is critical for accurate diagnosis, prognostic counseling, and appropriate therapeutic management.